Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): A systematic review and meta-analysis

Systematic Reviews

Volumn 1, Issue 1, 2009, Pages

  Alajbegovic, Sanjin ^a   Sanders, John W ^b   Atherly, Deborah E ^c   Riddle, Mark S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c PATH   (United States)

Author keywords

Chemoprophylaxis; Fluoroquinolone; Meta analysis; Rifaximin; Systematic review; Travelers' diarrhea

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMYCIN; RIFAXIMIN;

ANTIBIOTIC PROPHYLAXIS; DIARRHEA; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRAVEL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; DIARRHEA; FLUOROQUINOLONES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS; TRAVEL;

EID: 84876394559     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-1-39     Document Type: Article

References (50)

1. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009, 80:609-614.
2. Riddle MS, Halvorson HA, Shiau D, Althoff J, Monteville MR, Shaheen H, Horvath EP, Armstrong AW. Acute gastrointestinal infection, respiratory illness, and noncombat injury among US military personnel during Operation Bright Star 2005, in Northern Egypt. J Travel Med 2007, 14:392-401. 10.1111/j.1708-8305.2007.00159.x, 17995535.
3. Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin Infect Dis 2005, 41(Suppl 8):S531-S535.
4. Heywood AE, Zhang M, MacIntyre CR, Seale H. Travel risk behaviours and uptake of pre-travel health preventions by university students in Australia. BMC Infect Dis 2012, 12:43. 10.1186/1471-2334-12-43, 3305552, 22339735.
5. Yanni EA, Marano N, Han P, Edelson PJ, Blumensaadt S, Becker M, Dwyer S, Crocker K, Daley T, Davis X, Gallagher N, Balaban V, McCarron M, Mounts A, Lipman H, Brown C, Kozarsky P. Knowledge, attitudes, and practices of US travelers to Asia regarding seasonal influenza and H5N1 avian influenza prevention measures. J Travel Med 2010, 17:374-381. 10.1111/j.1708-8305.2010.00458.x, 21050316.
6. Namikawa K, Iida T, Ouchi K, Kimura M. Knowledge, attitudes, and practices of Japanese travelers on infectious disease risks and immunization uptake. J Travel Med 2010, 17:171-175. 10.1111/j.1708-8305.2010.00405.x, 20536885.
7. Hartjes LB, Baumann LC, Henriques JB. Travel health risk perceptions and prevention behaviors of US study abroad students. J Travel Med 2009, 16:338-343. 10.1111/j.1708-8305.2009.00322.x, 19796105.
8. Steffen R, Connor BA. Vaccines in travel health: from risk assessment to priorities. J Travel Med 2005, 12:26-35.
9. Office of Medical Applications of Research, National Institutes of Health; NIH Consensus Development Conference Travelers' diarrhea. JAMA 1985, 253:2700-2704. Office of Medical Applications of Research, National Institutes of Health; NIH Consensus Development Conference.
10. Reves RR, Johnson PC, Ericsson CD, DuPont HL. A cost-effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers' diarrhea. Arch Intern Med 1988, 148:2421-2427. 10.1001/archinte.1988.00380110071015, 3142381.
11. Thomson MA, Booth IW. Treatment of traveller's diarrhoea: economic aspects. Pharmacoeconomics 1996, 9:382-391. 10.2165/00019053-199609050-00002, 10160251.
12. DuPont HL. New insights and directions in travelers' diarrhea. Gastroenterol Clin North Am 2006, 35:337-353. viii-ix, 10.1016/j.gtc.2006.03.008, 16880069.
13. Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005, 142:861-862.
14. Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia FJ, Fischer PR, Ryan ET, . Infectious Diseases Society of America The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1499-1539. 10.1086/508782, 17109284, Infectious Diseases Society of America.
15. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome: a meta-analysis. Am J Gastroenterol 2006, 101:1894-1899. 10.1111/j.1572-0241.2006.00654.x, 16928253.
16. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:535-544. 10.1111/j.1365-2036.2007.03399.x, 17661757.
17. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2009, 26:17-25.
18. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther 2006, 4:417-427. 10.1586/14787210.4.3.417, 16771619.
19. Ericsson CD. Travellers' diarrhoea. Int J Antimicrob Agents 2003, 21:116-124. 10.1016/S0924-8579(02)00282-0, 12615374.
20. DuPont HL. Systematic review: prevention of travellers' diarrhoea. Aliment Pharmacol Ther 2008, 27:741-751. 10.1111/j.1365-2036.2008.03647.x, 18284650.
21. DuPont HL. Travellers' diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006, 66:303-314. 10.2165/00003495-200666030-00003, 16526819.
22. Chapman AS, Witkop CT, Escobar JD, Schlorman CA, DeMarcus LS, Marmer LM, Crum ME. Norovirus outbreak associated with person-to-person transmission, U.S. Air Force Academy, July 2011. MSMR 2011, 18:2-5.
23. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006, 25:3443-3457. 10.1002/sim.2380, 16345038.
24. Johnson PC, Ericsson CD, Morgan DR, Dupont HL, Cabada FJ. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob Agents Chemother 1986, 30:671-674. 10.1128/AAC.30.5.671, 176511, 3800342.
25. Cohen D, Shoham O, Orr N, Muhsen K. An inverse and independent association between Helicobacter pylori infection and the incidence of shigellosis and other diarrheal diseases. Clin Infect Dis 2012, 54:e35-e42. 10.1093/cid/cir916, 22157171.
26. DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005, 142:805-812.
27. Flores J, DuPont HL, Jiang ZD, Okhuysen PC, Melendez-Romero JH, Gonzalez-Estrada A, Carrillo I, Paredes M. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. J Travel Med 2011, 18:333-336. 10.1111/j.1708-8305.2011.00549.x, 21896097.
28. Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL. Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med 2010, 17:111-117. 10.1111/j.1708-8305.2009.00385.x, 20412178.
29. Parry H, Howard AJ, Galpin OP, Hassan SP. The prophylaxis of travellers' diarrhoea: a double blind placebo controlled trial of ciprofloxacin during a Himalayan expedition. J Infect 1994, 28:337-338. 10.1016/S0163-4453(94)92393-0, 8089525.
30. Rademaker CM, Hoepelman IM, Wolfhagen MJ, Beumer H, Rozenberg-Arska M, Verhoef J. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis 1989, 8:690-694. 10.1007/BF01963753, 2506034.
31. Wiström J, Norrby SR, Burman LG, Lundholm R, Jellheden B, Englund G. Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. J Antimicrob Chemother 1987, 20:563-574. 10.1093/jac/20.4.563, 3316152.
32. Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger CB, Haake R, Bourgeois AL. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006, 42:1283-1288. 10.1086/503039, 16586388.
33. Heck JE, Staneck JL, Cohen MB, Weckbach LS, Giannella RA, Hawkins J, Tosiello R. Prevention of travelers' diarrhea: ciprofloxacin versus trimethoprim/sulfamethoxazole in adult volunteers working in Latin America and the Caribbean. J Travel Med 1994, 1:136-142. 10.1111/j.1708-8305.1994.tb00580.x, 9815327.
34. Scott DA, Haberberger RL, Thornton SA, Hyams KC. Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am J Trop Med Hyg 1990, 42:160-164.
35. Yates JA, Stetz LC. Reiter's syndrome (reactive arthritis) and travelers' diarrhea. J Travel Med 2006, 13:54-56. 10.1111/j.1708-8305.2006.00009.x, 16412110.
36. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect 2004, 10:868-876. 10.1111/j.1469-0691.2004.00983.x, 15373879.
37. Tuteja AK, Talley NJ, Gelman SS, Alder SC, Thompson C, Tolman K, Hale DC. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci 2008, 53:271-276. 10.1007/s10620-007-9853-x, 17549631.
38. Parry SD, Stansfield R, Jelley D, Gregory W, Phillips E, Barton JR, Welfare MR. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study: Frequency of FGID After Gastroenteritis. Am J Gastroenterol 2003, 98:1970-1975.
39. Porter CK, Gloor K, Cash BD, Riddle MS. Risk of functional gastrointestinal disorders in U.S. military following self-reported diarrhea and vomiting during deployment. Dig Dis Sci 2011, 56:3262-3269. 10.1007/s10620-011-1762-3, 21643738.
40. Trivedi KH, Schlett CD, Tribble DR, Monteville MR, Sanders JW, Riddle MS. The impact of post-infectious functional gastrointestinal disorders and symptoms on the health-related quality of life of US military personnel returning from deployment to the Middle East. Dig Dis Sci 2011, 56:3602-3609. 10.1007/s10620-011-1766-z, 21647652.
41. Pitzurra R, Fried M, Rogler G, Rammert C, Tschopp A, Hatz C, Steffen R, Mutsch M. Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations. J Travel Med 2011, 18:250-256. 10.1111/j.1708-8305.2011.00529.x, 21722236.
42. Ilnyckyj A, Balachandra B, Elliott L, Choudhri S, Duerksen DR. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003, 98:596-599. 10.1111/j.1572-0241.2003.07297.x, 12650793.
43. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004, 99:1774-1778. 10.1111/j.1572-0241.2004.30435.x, 15330917.
44. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006, 43:898-901. 10.1086/507540, 16941373.
45. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410-413. 10.1136/gut.51.3.410, 1773359, 12171965.
46. Törnblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol 2007, 5:461-464. 10.1016/j.cgh.2007.01.007, 17445752.
47. Lundkvist J, Steffen R, Jönsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J Travel Med 2009, 16:28-34. 10.1111/j.1708-8305.2008.00270.x, 19192125.
48. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006, 24:21-37. 10.2165/00019053-200624010-00002, 16800160.
49. Lobel HO, Phillips-Howard PA, Brandling-Bennett AD, Steffen R, Campbell CC, Huong AY, Were JB, Moser R. Malaria incidence and prevention among European and North American travellers to Kenya. Bull World Health Organ 1990, 68:209-215. 2393137, 2364479.
50. Steffen R, Heusser R, Mächler R, Bruppacher R, Naef U, Chen D, Hofmann AM, Somaini B. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bull World Health Organ 1990, 68:313-322. 2393070, 2393977.